175 related articles for article (PubMed ID: 28828560)
1. Linking tuberous sclerosis complex, excessive mTOR signaling, and age-related neurodegeneration: a new association between TSC1 mutation and frontotemporal dementia.
Olney NT; Alquezar C; Ramos EM; Nana AL; Fong JC; Karydas AM; Taylor JB; Stephens ML; Argouarch AR; Van Berlo VA; Dokuru DR; Sherr EH; Jicha GA; Dillon WP; Desikan RS; De May M; Seeley WW; Coppola G; Miller BL; Kao AW
Acta Neuropathol; 2017 Nov; 134(5):813-816. PubMed ID: 28828560
[No Abstract] [Full Text] [Related]
2. Non-canonical functions of the tuberous sclerosis complex-Rheb signalling axis.
Neuman NA; Henske EP
EMBO Mol Med; 2011 Apr; 3(4):189-200. PubMed ID: 21412983
[TBL] [Abstract][Full Text] [Related]
3. PAK2 is an effector of TSC1/2 signaling independent of mTOR and a potential therapeutic target for Tuberous Sclerosis Complex.
Alves MM; Fuhler GM; Queiroz KC; Scholma J; Goorden S; Anink J; Spek CA; Hoogeveen-Westerveld M; Bruno MJ; Nellist M; Elgersma Y; Aronica E; Peppelenbosch MP
Sci Rep; 2015 Sep; 5():14534. PubMed ID: 26412398
[TBL] [Abstract][Full Text] [Related]
4. Functional assessment of TSC2 variants identified in individuals with tuberous sclerosis complex.
Hoogeveen-Westerveld M; Ekong R; Povey S; Mayer K; Lannoy N; Elmslie F; Bebin M; Dies K; Thompson C; Sparagana SP; Davies P; van Eeghen AM; Thiele EA; van den Ouweland A; Halley D; Nellist M
Hum Mutat; 2013 Jan; 34(1):167-75. PubMed ID: 22903760
[TBL] [Abstract][Full Text] [Related]
5. Regulation of YAP by mTOR and autophagy reveals a therapeutic target of tuberous sclerosis complex.
Liang N; Zhang C; Dill P; Panasyuk G; Pion D; Koka V; Gallazzini M; Olson EN; Lam H; Henske EP; Dong Z; Apte U; Pallet N; Johnson RL; Terzi F; Kwiatkowski DJ; Scoazec JY; Martignoni G; Pende M
J Exp Med; 2014 Oct; 211(11):2249-63. PubMed ID: 25288394
[TBL] [Abstract][Full Text] [Related]
6. Missense mutations to the TSC1 gene cause tuberous sclerosis complex.
Nellist M; van den Heuvel D; Schluep D; Exalto C; Goedbloed M; Maat-Kievit A; van Essen T; van Spaendonck-Zwarts K; Jansen F; Helderman P; Bartalini G; Vierimaa O; Penttinen M; van den Ende J; van den Ouweland A; Halley D
Eur J Hum Genet; 2009 Mar; 17(3):319-28. PubMed ID: 18830229
[TBL] [Abstract][Full Text] [Related]
7. The tuberous sclerosis complex.
Crino PB; Nathanson KL; Henske EP
N Engl J Med; 2006 Sep; 355(13):1345-56. PubMed ID: 17005952
[No Abstract] [Full Text] [Related]
8. Tuberous sclerosis: from tubers to mTOR.
Kwiatkowski DJ
Ann Hum Genet; 2003 Jan; 67(Pt 1):87-96. PubMed ID: 12556239
[TBL] [Abstract][Full Text] [Related]
9. Tuberous sclerosis complex inactivation disrupts melanogenesis via mTORC1 activation.
Cao J; Tyburczy ME; Moss J; Darling TN; Widlund HR; Kwiatkowski DJ
J Clin Invest; 2017 Jan; 127(1):349-364. PubMed ID: 27918305
[TBL] [Abstract][Full Text] [Related]
10. Excitatory/inhibitory synaptic imbalance leads to hippocampal hyperexcitability in mouse models of tuberous sclerosis.
Bateup HS; Johnson CA; Denefrio CL; Saulnier JL; Kornacker K; Sabatini BL
Neuron; 2013 May; 78(3):510-22. PubMed ID: 23664616
[TBL] [Abstract][Full Text] [Related]
11. Tsc1 deficiency-mediated mTOR hyperactivation in vascular endothelial cells causes angiogenesis defects and embryonic lethality.
Ma A; Wang L; Gao Y; Chang Z; Peng H; Zeng N; Gui YS; Tian X; Li X; Cai B; Zhang H; Xu KF
Hum Mol Genet; 2014 Feb; 23(3):693-705. PubMed ID: 24129405
[TBL] [Abstract][Full Text] [Related]
12. Aberrant beta-catenin signaling in tuberous sclerosis.
Mak BC; Kenerson HL; Aicher LD; Barnes EA; Yeung RS
Am J Pathol; 2005 Jul; 167(1):107-16. PubMed ID: 15972957
[TBL] [Abstract][Full Text] [Related]
13. Selective suppression of excessive GluN2C expression rescues early epilepsy in a tuberous sclerosis murine model.
Lozovaya N; Gataullina S; Tsintsadze T; Tsintsadze V; Pallesi-Pocachard E; Minlebaev M; Goriounova NA; Buhler E; Watrin F; Shityakov S; Becker AJ; Bordey A; Milh M; Scavarda D; Bulteau C; Dorfmuller G; Delalande O; Represa A; Cardoso C; Dulac O; Ben-Ari Y; Burnashev N
Nat Commun; 2014 Aug; 5():4563. PubMed ID: 25081057
[TBL] [Abstract][Full Text] [Related]
14. Rhebbing up mTOR: new insights on TSC1 and TSC2, and the pathogenesis of tuberous sclerosis.
Kwiatkowski DJ
Cancer Biol Ther; 2003; 2(5):471-6. PubMed ID: 14614311
[TBL] [Abstract][Full Text] [Related]
15. Heterozygous loss of TSC2 alters p53 signaling and human stem cell reprogramming.
Armstrong LC; Westlake G; Snow JP; Cawthon B; Armour E; Bowman AB; Ess KC
Hum Mol Genet; 2017 Dec; 26(23):4629-4641. PubMed ID: 28973543
[TBL] [Abstract][Full Text] [Related]
16. Tuberous sclerosis complex.
Hasbani DM; Crino PB
Handb Clin Neurol; 2018; 148():813-822. PubMed ID: 29478616
[TBL] [Abstract][Full Text] [Related]
17. Rapamycin for treating Tuberous sclerosis and Autism spectrum disorders.
Ehninger D; Silva AJ
Trends Mol Med; 2011 Feb; 17(2):78-87. PubMed ID: 21115397
[TBL] [Abstract][Full Text] [Related]
18. Pathogenesis of tuberous sclerosis subependymal giant cell astrocytomas: biallelic inactivation of TSC1 or TSC2 leads to mTOR activation.
Chan JA; Zhang H; Roberts PS; Jozwiak S; Wieslawa G; Lewin-Kowalik J; Kotulska K; Kwiatkowski DJ
J Neuropathol Exp Neurol; 2004 Dec; 63(12):1236-42. PubMed ID: 15624760
[TBL] [Abstract][Full Text] [Related]
19. Genetic Etiologies, Diagnosis, and Treatment of Tuberous Sclerosis Complex.
Salussolia CL; Klonowska K; Kwiatkowski DJ; Sahin M
Annu Rev Genomics Hum Genet; 2019 Aug; 20():217-240. PubMed ID: 31018109
[TBL] [Abstract][Full Text] [Related]
20. Impaired autophagy in neurons after disinhibition of mammalian target of rapamycin and its contribution to epileptogenesis.
McMahon J; Huang X; Yang J; Komatsu M; Yue Z; Qian J; Zhu X; Huang Y
J Neurosci; 2012 Nov; 32(45):15704-14. PubMed ID: 23136410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
